Stellar Biotechnologies Stock Price, News & Analysis (NASDAQ:SBOT)

$0.99 0.06 (6.45 %)
(As of 01/16/2018 10:52 AM ET)
Previous Close$0.93
Today's Range$0.94 - $1.04
52-Week Range$0.75 - $2.22
Volume216,900 shs
Average Volume207,478 shs
Market Capitalization$10.41 million
P/E Ratio-2.02
Dividend YieldN/A
Beta1.21

About Stellar Biotechnologies (NASDAQ:SBOT)

Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.

Receive SBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorBiotechnology & Medical Research - NEC
SymbolNASDAQ:SBOT
CUSIPN/A
Phone+1-805-4882800

Debt

Debt-to-Equity RatioN/A
Current Ratio21.09%
Quick Ratio20.91%

Price-To-Earnings

Trailing P/E Ratio-2.02040816326531
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales45.28
Cash FlowN/A
Price / CashN/A
Book Value$0.70 per share
Price / Book1.41

Profitability

Trailing EPS($0.49)
Net Income$-5,030,000.00
Net Margins-2,196.94%
Return on Equity-54.95%
Return on Assets-52.38%

Miscellaneous

Employees28
Outstanding Shares10,520,000

Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies Inc (NASDAQ:SBOT) posted its quarterly earnings results on Friday, December, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. Stellar Biotechnologies had a negative return on equity of 54.95% and a negative net margin of 2,196.94%. View Stellar Biotechnologies' Earnings History.

When will Stellar Biotechnologies make its next earnings announcement?

Stellar Biotechnologies is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Stellar Biotechnologies.

Who are some of Stellar Biotechnologies' key competitors?

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the folowing people:

  • Frank R. Oakes, Chairman of the Board, President, Chief Executive Officer (Age 65)
  • Kathi Niffenegger CPA, Chief Financial Officer, Secretary (Age 58)
  • Gregory T. Baxter Ph.D., Executive Vice President - Corporate Development (Age 57)
  • Tessie Mary Che Ph.D., Director (Age 65)
  • Paul Chun, Director
  • Daniel E. Morse Ph.D., Director (Age 74)
  • Charles Olson, Director
  • David L. Hill Ph.D., Independent Director (Age 65)

How do I buy Stellar Biotechnologies stock?

Shares of Stellar Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stellar Biotechnologies' stock price today?

One share of Stellar Biotechnologies stock can currently be purchased for approximately $0.99.

How big of a company is Stellar Biotechnologies?

Stellar Biotechnologies has a market capitalization of $10.41 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Stellar Biotechnologies employs 28 workers across the globe.

How can I contact Stellar Biotechnologies?

Stellar Biotechnologies' mailing address is 332 E Scott St, PORT HUENEME, CA 93041-2939, United States. The biotechnology company can be reached via phone at +1-805-4882800 or via email at [email protected]


MarketBeat Community Rating for Stellar Biotechnologies (SBOT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Stellar Biotechnologies (NASDAQ:SBOT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$4.00$4.00
Price Target Upside: N/AN/A79.37% upside79.37% upside

Stellar Biotechnologies (NASDAQ:SBOT) Consensus Price Target History

Price Target History for Stellar Biotechnologies (NASDAQ:SBOT)

Stellar Biotechnologies (NASDAQ:SBOT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2016Maxim GroupLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Stellar Biotechnologies (NASDAQ:SBOT) Earnings History and Estimates Chart

Earnings by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)

Stellar Biotechnologies (NASDAQ SBOT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
12/1/2017Q4 2017($0.14)($0.12)ViewN/AView Earnings Details
8/9/2017Q3 2017($0.12)($0.12)$0.34 million$0.02 millionViewN/AView Earnings Details
5/9/2017Q2 2017($0.15)($0.11)$0.33 million$0.06 millionViewN/AView Earnings Details
2/6/2017Q1 2017($0.10)($0.15)$0.31 million$0.14 millionViewN/AView Earnings Details
12/14/2016Q4 2016($0.13)ViewN/AView Earnings Details
8/9/2016Q3 2016($0.16)($0.14)ViewN/AView Earnings Details
5/9/2016Q2 2016($0.18)($0.10)ViewN/AView Earnings Details
2/8/2016Q1 2016($0.21)($0.19)ViewN/AView Earnings Details
12/14/2015Q4 2015($0.17)($0.19)ViewN/AView Earnings Details
5/11/2015Q2 2015($0.20)($0.20)ViewN/AView Earnings Details
2/9/2015Q1 2015($0.20)($0.20)ViewN/AView Earnings Details
11/13/2014Q4 2014($0.20)($0.20)ViewN/AView Earnings Details
7/10/2014Q3 2014($0.20)($0.10)ViewN/AView Earnings Details
1/30/2014Q1 2014($0.80)ViewN/AView Earnings Details
12/31/2013Q4 2013($1.80)ViewN/AView Earnings Details
10/18/2013Q3 2013($0.20)ViewN/AView Earnings Details
6/3/2013Q2 2013($0.70)ViewN/AView Earnings Details
3/6/2013Q3 2012($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Stellar Biotechnologies (NASDAQ:SBOT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.11)($0.11)($0.11)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Stellar Biotechnologies (NASDAQ:SBOT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stellar Biotechnologies (NASDAQ SBOT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Stellar Biotechnologies (NASDAQ SBOT) News Headlines

Source:
DateHeadline
Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 12:57 PM
Stellar Biotechnologies, Inc. to Post Q1 2018 Earnings of ($0.14) Per Share, Zacks Investment Research Forecasts (SBOT)Stellar Biotechnologies, Inc. to Post Q1 2018 Earnings of ($0.14) Per Share, Zacks Investment Research Forecasts (SBOT)
www.americanbankingnews.com - December 8 at 8:36 AM
SBOT: Important Clinical Program Related Milestones UpcomingSBOT: Important Clinical Program Related Milestones Upcoming
finance.yahoo.com - December 6 at 3:42 PM
Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 12:59 PM
Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - December 2 at 8:03 AM
Stellar Biotechnologies Reports Fiscal Year 2017 Financial ResultsStellar Biotechnologies Reports Fiscal Year 2017 Financial Results
finance.yahoo.com - December 1 at 6:29 PM
SBOT: Araclon’s Ph IIb Lupus Study Could Read-Out 1H 2018SBOT: Araclon’s Ph IIb Lupus Study Could Read-Out 1H 2018
finance.yahoo.com - November 30 at 3:41 PM
Should You Buy Stellar Biotechnologies Inc (SBOT) Now?Should You Buy Stellar Biotechnologies Inc (SBOT) Now?
finance.yahoo.com - October 18 at 1:42 AM
SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018SBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018
finance.yahoo.com - September 6 at 8:00 AM
Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017Stellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:22 AM
Stellar Biotechnologies, Inc. (SBOT) Releases Quarterly  Earnings Results, Hits EstimatesStellar Biotechnologies, Inc. (SBOT) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - August 10 at 11:28 PM
Stellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 10 at 8:20 PM
Stellar Biotechnologies Reports Third Quarter 2017 Financial ResultsStellar Biotechnologies Reports Third Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:41 AM
Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on MondayStellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 11:40 AM
Stellar Biotechnologies Expands Operations Team - PR Newswire (press release)Stellar Biotechnologies Expands Operations Team - PR Newswire (press release)
www.prnewswire.com - June 8 at 3:00 AM
Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 11:02 AM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters toSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
biz.yahoo.com - March 29 at 8:32 AM
Stellar Biotechnologies (SBOT) to Sell Immunogen & Vaccine Technology to MatrivaxStellar Biotechnologies (SBOT) to Sell 'Immunogen & Vaccine Technology' to Matrivax
www.streetinsider.com - March 13 at 7:24 PM
Stellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine TechnologyStellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
us.rd.yahoo.com - March 13 at 7:24 PM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, FinanSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Finan
biz.yahoo.com - March 13 at 7:24 PM
Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)Amaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)
www.prnewswire.com - March 2 at 1:02 AM
Amaran Biotechnology Selects Stellar KLH for Cancer VaccinesAmaran Biotechnology Selects Stellar KLH for Cancer Vaccines
us.rd.yahoo.com - March 1 at 10:06 AM
Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)Stellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - February 7 at 8:08 AM
8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes
us.rd.yahoo.com - February 7 at 12:53 AM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - December 14 at 10:01 PM
STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, FinancialSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial
biz.yahoo.com - December 9 at 7:36 PM

SEC Filings

Stellar Biotechnologies (NASDAQ:SBOT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Stellar Biotechnologies (NASDAQ SBOT) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.